Chemical Structure Of Thalidomide (Thalomid 01)
Thalomid Capsule
Product Images NDC 59572-215
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Thalomid (NDC 59572-215). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Celgene Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Kaplan-meier Plot Of Time To Disease Progression (Thalomid 02)
The text describes a graph showing the proportion of subjects with or without progression, with time (in weeks) on the x-axis and the proportion on the y-axis. There are three treatment groups represented: Trol/Dex, Placebo/Dex, and a group of censored data. The specific results of the graph cannot be discerned from the provided text.*
50 mg Blister Pack (Thalomid 03)
This text includes information about a prescription drug called THALOMID, which can cause severe birth defects and other medical problems. It also provides instructions for patients, including women of childbearing age, on how to take the medication responsibly and avoid negative side effects. The text also mentions a confidential survey that patients must take to ensure they can follow information designed to prevent serious risks to unborn babies.*
50 mg Carton (Thalomid 04)
This text describes guidelines for pharmacists dispensing Thalidomide, a drug used for multiple myeloma. The THALOMID REMS program requires counseling for every patient and prescriptions must contain an authorization number and patient risk category. The pharmacist must only dispense a 4-week supply, and no refills or telephone prescriptions are allowed. Additionally, the drug poses severe risks to unborn babies and should not be used by pregnant women or those planning to be pregnant while using the drug. It is stored in a temperature-controlled environment and is supplied in opaque blister packs containing 28 capsules each.*
50 mg (Single Unit Blister Pack)
50 mg (Single Unit Carton)
The text is a set of instructions and guidelines for pharmacists working in pharmacies that distribute a medication called Thalomid (thalidomide). The instructions include reviewing orders and counseling patients before dispensing the medication, only accepting prescriptions with specific authorization numbers, not accepting automated or telephone prescriptions, and dispensing blister packs intact with enclosed prescribing information. There are also specific storage guidelines for the medication.*
100 mg Blister Pack (Thalomid 07)
This is an instruction for the medicine "THALOMID" (thalidomide). It contains guidelines for pharmacists for prescribing and dispensing the medicine and counseling patients. The instructions also contain information for patients on how to take the medicine and prevent pregnancy while on it. A warning is provided about the severe birth defects that can occur if taken while pregnant, and guidelines for men and women to follow when using the medicine are given. Multiple texts appear on the page, including warnings and legal disclaimers, information on potential side effects, and directions for obtaining THALOMID.*
100 mg Carton (Thalomid 08)
This is a pharmaceutical product package of Thalomid, containing blister packs with 5 packs, each with 28 capsules of 100 mg Thalidomide. It suggests that the pharmacist will dispense the product with its enclosed prescribing information and medication guide. There is also a reference to THALOMID REMS program.*
150 mg Blister Pack (Thalomid 09)
This is a collection of text fragments, including medical and pharmaceutical information about THALOMID®, such as usage guidelines, warnings, and potential side effects. It includes instructions for pharmacists to dispense THALOMID®, as well as warnings for women who are pregnant or breastfeeding and for men who may father a child while taking the drug. The text also includes general guidelines for taking THALOMID® and a warning that it can cause severe birth defects.*
150 mg Carton (Thalomid 10)
200 mg Blister Pack (Thalomid 11)
200 mg Carton (Thalomid 12)
This appears to be a medication label for a drug called THALOMID, contained in blister packs with 28 capsules each. The label includes prescribing information and warnings about the drug, which may be used for multiple myeloma in adults but may be associated with increased risk of venous thromboembolic events. Information is also provided on how to dispense the medication.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
